bit.bio Expands Independent Ethics and Sustainability Board as Part of Commitment to Being a Purpose Driven Company – QNT Press Release


  • Dr Enrica Alteri has extensive experience in drug discovery and clinical safety and worked at the European Medicines Agency for 8 years, serving on its Executive Board

  • Prof Jeffrey Skopek is Associate Professor of Law at the University of Cambridge and Deputy Director of its Centre for Law, Medicine and Life Sciences.

Today bit.bio welcomes two new members to its independent Ethics and Sustainability Board to further support the company’s commitment to being a purpose led, ethical organisation. bit.bio is working towards a future in which precision engineered human cells enable biomedical innovation (UN SDG9 ) and a new generation of cures (UN SDG3).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221024005538/en/

From left to right: Ethics and Sustainability Board members Dr Enrica Alteri, Professor Marie-Claire Cordonier Segger (Chair of the Board), Professor Jeffrey Skopek.(Photo: Business Wire)

The new advisors will provide important and independent guidance as bit.bio scales their proprietary synthetic biology cell identity coding platform, creating products and solutions based on human cells that can transform healthcare from basic research and drug discovery to next generation cell based therapies.

The Ethics and Sustainability Board is chaired by Professor Marie-Claire Cordonier Segger, an international expert in sustainability, law and public policy. It was established by Prof Cordonier Segger in the early days of bit.bio. The board’s role is to review company strategy , from R&D and clinical translation to commercialisation and operations and provide guidance and recommendations as well as align it with UN sustainable development goals.

New board member Dr Enrica Alteri spent 7 years in drug discovery and 5 years in clinical safety at Ciba-Geigy/Novartis and then went on to lead the Pharmacovigilance and Risk Management team at Serono in Geneva. In 2012 she joined the European Medicines Agency, where she held various senior positions and was a member of the Executive Board until 2020.

Commenting on her appointment, Dr Alteri said:

“Working with the European regulatory agency allowed me to see ideas turning into products and helping patients. This is a remarkable journey and needs to be done …

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center